Healthcare Sales & Marketing Network News: ridaforolimus

Searching News Database: ridaforolimus

HSMN NewsFeed - 14 Jan 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
Devices Interventional Cardiology

HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 5 May 2010
Merck Acquires Development and Commercialization Rights to Investigational mTOR Inhibitor Ridaforolimus from ARIAD Pharmaceuticals, Inc.
Biopharmaceuticals Oncology Acquisitions

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.